Provided is a pharmaceutical composition, which comprises 5-[(3R)-1-acryloylpyrrolidin-3-yl]oxy}-6-ethyl-3-(4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-pyrazine-2-carboxamide (hereinafter referred to as "compound A") or a pharmaceutically acceptable salt thereof, and is stabilized. The pharmaceutical composition comprises compound A or a pharmaceutically acceptable salt thereof, and a pharmaceutical additive having a difference in water activity value of 0.1 or more, and is stabilized.
本发明提供了一种药物组合物,它包含 5-[(3R)-
1-丙烯酰基
吡咯烷-3-基]氧基}-6-乙基-3-(4-[4-(4-甲基
哌嗪-1-基)
哌啶-1-基]苯基}
氨基)-
吡嗪-2-甲酰胺(以下简称 "化合物 A")或其药学上可接受的盐,并已稳定。该药物组合物包含化合物 A 或其药学上可接受的盐,以及
水活性值相差 0.1 或更多的药物添加剂,并已稳定。